Aosaikang: The results of the Phase III clinical study of Liraglutide Tablets were published in The Lancet Respiratory Medicine

Aosaikang announced that the Phase III clinical research results of its innovative drug Liratinib tablets were recently published in the international top medical journal The Lancet Respiratory Medicine. Liratinib tablets are third-generation epidermal growth factor receptor tyrosine kinase inhibitors used for first-line and second-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR mutations